Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Mirati Therapeutics Inc

CUSIP: 60468T905 | 11 institutional holders

Quarters

Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022

Compare Detailed Historical Funds Options 13D/13G Peers Targeting Trading Summary Profile